Gynecologic Oncology Fellowship
University of Oklahoma
Obstetrics and Gynecology Residency
Temple University Hospital
Temple University School of Medicine
Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs 2009; 27(4):304-318.
Landrum LM, Moore KN, Myers TK, Lanneau GS, Walker JL, Gold MA. “Stage IVb endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes?” Gynecologic Oncology 2009; 112:337-341.
Moore KN. Alward EK, Frank SG, Landrum LM. Myers TK et al. Adjuvant chemotherapy for the “oldest old” ovarian cancer patients: can we anticipate toxicity related treatment failure in a vulnerable population? Cancer 2009; 115: 1472-1480 and Cancer 23 February 2009
Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecologic Oncology 2008; 108: 342-347.
Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS. Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecology Oncology 2008; 110(2):133-139.
Myers TKN. McMeekin DS. Endometrial Cancer. Conn’s Current Therapy 2007/2008